4//SEC Filing
deGoa Damian 4
Accession 0001104659-20-135897
CIK 0001819576other
Filed
Dec 14, 7:00 PM ET
Accepted
Dec 15, 9:12 PM ET
Size
6.4 KB
Accession
0001104659-20-135897
Insider Transaction Report
Form 4
Liquidia CorpLQDA
deGoa Damian
Director
Transactions
- Award
Nonstatutory Stock Option (right to buy)
2020-12-14+2,000,000→ 2,000,000 totalExercise: $3.00Exp: 2030-12-14→ Common Stock (2,000,000 underlying)
Footnotes (2)
- [F1]The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on December 14, 2024; provided, however, that, notwithstanding the foregoing vesting schedule, (x) 25% of the shares of common stock underlying the option will vest upon U.S. Food and Drug Administration tentative approval of the issuer's New Drug Application for LIQ861 prior to June 30, 2022 and
- [F2](y) 25% of the shares of common stock underlying the option will vest upon commercial availability of subcutaneous treprostinil with cartridge supplies sufficient to support the market for one year prior to December 31, 2021; provided, further, that upon a Change in Control (as defined in the accompanying Nonstatutory Stock Option Agreement) 100% of the unvested portion of the option shall become vested and exercisable as of the date of the Change in Control, provided that Mr. deGoa is actively employed with Liquidia Technologies, Inc. on such date.
Documents
Issuer
Liquidia Corp
CIK 0001819576
Entity typeother
Related Parties
1- filerCIK 0001836165
Filing Metadata
- Form type
- 4
- Filed
- Dec 14, 7:00 PM ET
- Accepted
- Dec 15, 9:12 PM ET
- Size
- 6.4 KB